BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast to KBM7 cells, HAP1 cells grow adherent and are not dependent on BCR (Fig. 5c), while Bcr-Abl inhibitors represent the first-line therapy in CML [60].